RNA (Atrium Therapeutics) FCF Margin %: -169.29% (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $12.80
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics FCF Margin %?

Atrium Therapeutics RNA +0.16% 12 FCF Margin % is -169.29% as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Atrium Therapeutics ranks worse than 62.88% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Atrium Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-33.24 Mil. Atrium Therapeutics's Revenue for the three months ended in Mar. 2026 was $19.64 Mil. Therefore, Atrium Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -169.29%.

As of today, Atrium Therapeutics's current FCF Yield % is -23.92%.

The historical rank and industry rank for Atrium Therapeutics's FCF Margin % or its related term are showing as below:

RNA' s FCF Margin % Range Over the Past 10 Years
Min: -256.14   Med: -209.41   Max: 574.25
Current: -256.14

During the past 3 years, the highest FCF Margin % of Atrium Therapeutics was 574.25%. The lowest was -256.14%. And the median was -209.41%.

RNA's FCF Margin % is ranked worse than
62.88% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs RNA: -256.14

Atrium Therapeutics FCF Margin % Related Terms

Atrium Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics FCF Margin % Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
FCF Margin %
574.25 -209.41 -228.67

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial -285.27 -705.85 0.00 -2,241.21 -169.29

RNA vs RNAC, KROS, ARCT: FCF Margin % Comparison

For the Biotechnology subindustry, Atrium Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrium Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Atrium Therapeutics's FCF Margin % falls into.


RNA
12GF Score
Atrium Therapeutics Inc RNA
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Atrium Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-42.574/18.618
=-228.67 %

Atrium Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-33.241/19.635
=-169.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -169.29% mean?
Atrium Therapeutics (RNA) has a FCF Margin % of -169.29% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Atrium Therapeutics and its competitors. According to the industry distribution chart, Atrium Therapeutics ranks #603 out of 959 companies in the Biotechnology industry, placing it in the top 62.9%.
Is Atrium Therapeutics' FCF Margin % too high?
Atrium Therapeutics' current FCF Margin % is -169.29%. Based on the distribution chart, Atrium Therapeutics ranks #603 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' FCF Margin % compare to RNAC and KROS?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #603 out of 959 companies for FCF Margin %. This places Atrium Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current FCF Margin % is -169.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current FCF Margin % of -169.29%. The current FCF Margin % is -169.29%. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current FCF Margin % is -169.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.80
Price